Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia
- 100% complete remission rate in newly diagnosed patients
- Encouraging clinical activity in refractory/relapsed patients
- Encouraging safety profile and tolerability of ziftomenib
- No differentiation syndrome events reported
- Initiation of Phase 1b dose validation/expansion in combination with standard treatments in newly diagnosed patients
- Strong financial position with cash runway expected into 2027
- None.
The complete remission (CR) rate of 100% reported with the combination of ziftomenib and 7+3 in newly diagnosed NPM1-mutant and KMT2A-rearranged acute myeloid leukemia (AML) is a significant clinical finding. From an oncological perspective, achieving CR is a key milestone in AML treatment, as it indicates the absence of detectable cancer following therapy. This high rate of CR, particularly in a cohort with adverse risk features, suggests that ziftomenib may offer a substantial clinical benefit over existing therapies. It is also noteworthy that no differentiation syndrome, a potentially fatal complication, was observed, indicating a favorable safety profile for ziftomenib in this context.
Furthermore, the reported 56% CR/CRh rate in menin inhibitor naïve patients with relapsed/refractory (R/R) AML treated with ziftomenib and venetoclax/azacitidine (ven/aza) is promising, especially considering the limited effective treatment options for this patient population. This suggests that ziftomenib could become an important addition to the current AML treatment paradigm. The fact that 80% of patients remain on trial is encouraging, as it may indicate sustained tolerability and efficacy of the drug.
From a research perspective, the preliminary data from the KOMET-007 trial is noteworthy for several reasons. First, the rapid enrollment and retention of patients in the trial underscores the medical community's interest in ziftomenib as a potential treatment for AML. The lack of dose-limiting toxicities and drug interactions at the 200 mg dose level is a positive sign for the drug's safety profile. The ongoing enrollment at the 400 mg dose will provide further insights into the optimal dosing strategy for ziftomenib.
Second, the data suggests that ziftomenib could address a significant unmet medical need in AML, particularly for patients with NPM1-m and KMT2A-r mutations. The planned expansion into a Phase 1b trial for newly diagnosed patients without adverse risk features indicates a strategic move to broaden the potential patient population. The financial position of Kura Oncology, with a cash runway into 2027, supports the continued investment in the development of ziftomenib, which is critical for advancing this treatment through the necessary clinical trials.
For investors and stakeholders in Kura Oncology, the preliminary clinical data from the KOMET-007 trial could be a catalyst for the company's stock valuation. The high CR rate and favorable safety profile of ziftomenib could position the drug as a competitive player in the AML market, potentially capturing a significant market share if approved. The company's strong cash position, sufficient to fund operations into 2027, reduces immediate financial risk and allows for aggressive investment in research and pre-commercial activities, which is crucial for a biopharmaceutical firm at this stage.
The investor event is an opportunity for Kura to further articulate the drug's value proposition and development strategy, which could impact investor sentiment and stock performance. The progress in the KOMET-007 trial and the upcoming enrollment completion of the Phase 2 registration-directed KOMET-001 trial are key milestones that investors should monitor, as they will provide additional data points to evaluate ziftomenib's efficacy and market potential.
– No differentiation syndrome events reported –
–
–
–
– 200 mg dose of ziftomenib cleared in ven/aza cohorts, enrollment at 400 mg dose ongoing –
– Management to host virtual investor event today at 8:00 a.m. ET –
SAN DIEGO, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported preliminary clinical data from the first 20 patients in KOMET-007, a Phase 1 dose-escalation trial of the Company’s potent and selective menin inhibitor, ziftomenib, in combination with standards of care, including cytarabine/daunorubicin (7+3) and venetoclax/azacitidine (ven/aza), in patients with NPM1-mutant (NPM1-m) and KMT2A-rearranged (KMT2A-r) acute myeloid leukemia (AML).
The first 20 patients were enrolled in KOMET-007 between July 2023 and November 2023, including five newly diagnosed patients with adverse risk1 NPM1-m or KMT2A-r AML and 15 patients with refractory/relapsed (R/R) NPM1-m or KMT2A-r AML.
Continuous daily dosing of ziftomenib at 200 mg QD has been well tolerated and the safety profile consistent with features of underlying disease and backbone therapies. No differentiation syndrome events of any grade were reported, and no dose-limiting toxicities, evidence of QTc prolongation, drug-drug interactions or additive myelosuppression were observed.
As of the data cutoff on January 11, 2024, all newly diagnosed patients treated with ziftomenib and 7+3 achieved a complete remission (CR) with full count recovery, for a CR rate of
The overall response rate (ORR) among R/R patients treated with ziftomenib and ven/aza was
As of the data cutoff,
“Ziftomenib is one of the most exciting investigational agents being studied in AML, and I am thrilled to see the rapid pace of accrual into this first-in-human combinational study,” said Amer Zeidan, MBBS, MHS, interim chief of the Division of Hematologic Malignancies, Director of Hematology Early Therapeutics Research at Yale Cancer Center and lead investigator of the KOMET-007 trial. “In this first public release of early data from the KOMET-007 trial, ziftomenib demonstrates an encouraging safety and tolerability profile in combination with 7+3 and ven/aza, enabling continuous administration while mitigating the risk of differentiation syndrome. The combinations demonstrate encouraging preliminary evidence of clinical activity in patients with refractory/relapsed disease after failure of other agents, including venetoclax, a setting with very limited effective treatment options. Further, the fact that most patients remain on study as of the data cutoff is notable in such difficult-to-treat patient populations.”
The 200 mg dose of ziftomenib has been cleared in the R/R ven/aza cohorts and enrollment at the 400 mg dose is ongoing. Upon determination of a recommended Phase 2 dose, Kura plans to initiate a Phase 1b dose validation/expansion in combination with ven/aza in newly diagnosed patients with NPM1-m (without adverse risk) or KMT2A-r AML.
“We are highly encouraged by these preliminary combination data for ziftomenib and believe they support advancement into the frontline AML population,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. “Given that ziftomenib targets foundational mutations at the core of up to
Virtual Investor Event
Kura will host a virtual investor event featuring company management and investigators from the KOMET-007 trial of ziftomenib today at 8:00 a.m. ET. The live call may be accessed by dialing (800) 715-9871 for domestic callers and (646) 307-1963 for international callers and entering the conference ID: 7854712. A live webcast will be available here and in the Investors section of Kura’s website, with an archived replay available shortly after the event.
About Acute Myeloid Leukemia
AML is the most common acute leukemia in adults and begins when the bone marrow makes abnormal myeloblasts (white blood cells), red blood cells or platelets. Despite the many available treatments for AML, prognosis for patients remains poor and a high unmet need remains. The menin pathway is considered a driver for multiple genetic alterations of the disease, of which NPM1-mutations are among the most common, representing approximately
About Ziftomenib
Ziftomenib is a novel, once-daily, oral investigational drug candidate targeting the menin-KMT2A/MLL protein-protein interaction for treatment of genetically defined AML patients with high unmet need. In preclinical models, ziftomenib inhibits the KMT2A/MLL protein complex and exhibits downstream effects on HOXA9/MEIS1 expression and potent anti-leukemic activity in genetically defined preclinical models of AML. Ziftomenib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of AML. Additional information about clinical trials for ziftomenib can be found at kuraoncology.com/clinical-trials/#ziftomenib.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined AML patients with high unmet need. Kura is currently enrolling patients in a Phase 2 registration-directed trial of ziftomenib in NPM1-m R/R AML (KOMET-001). The Company is also conducting a series of studies to evaluate ziftomenib in combination with current standards of care, beginning with ven/aza and 7+3 in NPM1-m and KMT2A-r newly diagnosed and R/R AML (KOMET-007). Tipifarnib, a potent and selective farnesyl transferase inhibitor (FTI), is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma (KURRENT-HN). Kura is also evaluating KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial as a monotherapy and in combination with cabozantinib in clear cell renal cell carcinoma and adagrasib in KRASG12C-mutated non-small cell lung cancer (FIT-001). For additional information, please visit Kura’s website at www.kuraoncology.com and follow us on X and LinkedIn.
Forward-Looking Statements
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and therapeutic potential of ziftomenib, potential benefits of combining ziftomenib with appropriate standards of care, plans regarding future clinical trials in the ziftomenib program, plans and expected timing for enrollment in the Phase 2 registration-directed trial of ziftomenib, and the Company’s cash runway. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Kura may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings, applications and other interactions with regulatory bodies, risks associated with reliance on third parties to successfully conduct clinical trials, risks associated with Kura’s cash needs, the risks associated with reliance on outside financing to meet capital requirements, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “promise,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to the Company's periodic and other filings with the Securities and Exchange Commission (SEC), including the Company’s Form 10-Q for the quarter ended September 30, 2023 filed with the SEC on November 2, 2023, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Kura assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Amer Zeidan has consulted and received honoraria from Kura. Opinions expressed are his own and do not necessarily represent those of his employer.
Contacts
Investors:
Pete De Spain
Executive Vice President, Investor Relations &
Corporate Communications
(858) 500-8833
pete@kuraoncology.com
Media:
Alexandra Weingarten
Associate Director, Investor Relations &
Corporate Communications
(858) 500-8822
alexandra@kuraoncology.com
1 Age > 60 years and/or treatment-related AML and/or adverse risk cytogenetics per European LeukemiaNet (ELN)
2 CR with partial hematologic recovery
3 Issa G, et al. Blood Adv 2023;7(6):933-42.
4 Issa GC, et al. Blood Cancer J. 2021;11(9):162.
FAQ
What is the ticker symbol for Kura Oncology, Inc.?
What is the Phase of the clinical trial mentioned in the PR?
What was the complete remission rate in newly diagnosed patients?
What is the safety profile of ziftomenib?
What is the financial position of Kura Oncology, Inc.?
